PT-141 (Bremelanotide) Renal Protection or Renal Risk: What the Clinical Evidence Shows

What Is Bremelanotide and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist that binds primarily to MC1R, MC3R, and MC4R receptors distributed across the central nervous system and peripheral tissues, including the kidney [1]. The drug was approved by the FDA on June 21, 2019, under the brand name Vyleesi for HSDD in premenopausal women [2]. Its mechanism is entirely distinct from phosphodiesterase-5 inhibitors: instead of increasing genital blood flow directly, bremelanotide modulates central dopaminergic and oxytocinergic pathways to increase sexual desire [3].

Melanocortin Receptors in Non-Sexual Tissues

Melanocortin receptors are not confined to the hypothalamus. MC1R and MC3R are expressed in renal proximal tubule cells, glomerular mesangial cells, and podocytes [4]. This distribution means that any systemic melanocortin agonist, including bremelanotide, may interact with renal tissue whether the prescriber intends it or not. Whether that interaction is protective or harmful depends on dose, duration, underlying renal status, and receptor subtype engaged.

The RECONNECT Phase 3 Program

The key RECONNECT trials enrolled 1,267 premenopausal women across two identically designed Phase 3 randomized controlled trials [5]. Participants received bremelanotide 1.75 mg or placebo subcutaneously as needed over 24 weeks. Co-primary endpoints were change from baseline in the Female Sexual Function Index desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 score. The trials demonstrated statistically significant improvements on both endpoints (P<0.001 for desire domain; P<0.001 for FSDS-DAO Item 13) [5]. Renal adverse events were not listed among the treatment-emergent adverse events occurring in more than 2% of participants, suggesting no gross signal of acute kidney injury at the approved dose.

Bremelanotide Pharmacokinetics and Renal Elimination

Understanding where bremelanotide goes after injection matters for anyone prescribing to patients with reduced kidney function [6].

Absorption and Distribution

After a 1.75 mg subcutaneous dose, peak plasma concentration (Cmax) is reached in approximately 1 hour. The volume of distribution at steady state is roughly 40 L, indicating moderate tissue penetration beyond plasma [6]. Plasma protein binding is approximately 21%, which is low relative to most peptide drugs, leaving a larger free fraction available for filtration.

Hepatic Cleavage and Urinary Excretion

Bremelanotide is metabolized primarily through peptide bond hydrolysis in the liver and, to a lesser degree, in the kidney itself [6]. The FDA label reports that approximately 64.8% of radioactivity from a radiolabeled dose was recovered in urine and 22.8% in feces over 14 days, making renal excretion the dominant route for metabolite elimination [2]. This figure has direct clinical relevance: a patient with an eGFR of 20 mL/min cannot clear those metabolites at the same rate as a patient with an eGFR of 90 mL/min, raising the theoretical risk of accumulation with repeated dosing.

Impact of Renal Impairment on Exposure

The FDA prescribing information states that no formal pharmacokinetic study was conducted specifically in patients with severe renal impairment [2]. Population pharmacokinetic modeling suggests that AUC increases by approximately 40% in patients with severe impairment (eGFR <30 mL/min/1.73 m²). The label does not recommend a specific dose adjustment but advises clinicians to use caution in this population [2]. Patients on hemodialysis were excluded from the RECONNECT trials, so no safety or efficacy data exist for this subgroup [5].

Does Bremelanotide Protect the Kidney? Preclinical and Mechanistic Evidence

The possibility that melanocortin agonists protect renal tissue is not speculative. Several published preclinical studies point to real anti-inflammatory and anti-apoptotic signaling through MC1R in the kidney [4].

Melanocortin Agonism and Renal Inflammation

A study by Lindborg and colleagues published in the American Journal of Physiology demonstrated that MC1R activation in murine models of ischemia-reperfusion injury reduced tubular apoptosis and decreased interleukin-6 and tumor necrosis factor-alpha expression in renal tissue [4]. The proposed mechanism involves downstream suppression of NF-kB signaling in tubular epithelial cells, the same pathway that drives injury in acute kidney injury and progressive CKD [7].

MC3R and Mesangial Cell Protection

MC3R expressed in glomerular mesangial cells responds to alpha-MSH (alpha-melanocyte-stimulating hormone), the natural ligand that bremelanotide structurally mimics [3]. Activation of MC3R in isolated mesangial cells has been shown to reduce extracellular matrix protein deposition in vitro, a process central to glomerulosclerosis [7]. Bremelanotide binds MC3R with a Ki of approximately 5.3 nM, which is pharmacologically significant, though systemic concentrations after a single 1.75 mg dose likely do not sustain receptor occupancy long enough to produce the effects seen in chronic animal models.

Why Preclinical Data Do Not Translate Automatically to Patients

Animal models of renal ischemia typically use continuous infusion or suprapharmacologic doses of melanocortin agonists. A single as-needed subcutaneous injection of 1.75 mg bremelanotide produces transient receptor engagement lasting 6 to 12 hours at most [6]. No prospective clinical trial has measured kidney biomarkers (cystatin C, NGAL, KIM-1) before and after bremelanotide dosing in patients with or without CKD. The nephroprotective narrative, while mechanistically plausible, remains unproven in humans at the approved dose and schedule.

Renal Risk Stratification: A Clinical Decision Framework

When a patient with known CKD or reduced eGFR asks about bremelanotide, clinicians need a structured approach rather than a binary yes-or-no answer. The table below organizes risk by eGFR stage.

| eGFR Stage | eGFR Range (mL/min/1.73m²) | Bremelanotide Guidance | |---|---|---| | G1 (Normal) | ≥90 | Standard 1.75 mg dose; no restriction | | G2 (Mildly decreased) | 60-89 | Standard dose; routine monitoring | | G3a | 45-59 | Standard dose; note BP effect; baseline renal panel | | G3b | 30-44 | Use with caution; monitor BP and serum creatinine | | G4 (Severe) | 15-29 | PK data limited; ~40% AUC increase expected; low-frequency dosing preferred | | G5 / ESRD / HD | <15 or dialysis | No safety data; avoid unless benefit clearly outweighs risk |

The blood pressure concern in CKD patients deserves emphasis. Bremelanotide produces a mean transient decrease in systolic BP of approximately 6 mmHg and diastolic BP of approximately 4 mmHg, peaking around 4 hours post-dose and resolving by 12 hours [2]. Patients with CKD stage 3b or higher often already have autonomic dysfunction and may experience exaggerated hypotension, which in turn can reduce renal perfusion pressure and precipitate a prerenal insult.

Cardiovascular Overlap and Contraindications

The FDA label contraindicates bremelanotide in patients with known cardiovascular disease or high cardiovascular risk [2]. CKD stage 3 and above is itself a major independent cardiovascular risk factor per the KDIGO 2024 guidelines [8]. This overlap means that a substantial proportion of patients who might ask about bremelanotide for HSDD are already in a category where the drug is contraindicated for cardiovascular, not purely renal, reasons.

Drug Interactions Relevant to Renal Patients

Bremelanotide can slow gastric emptying by approximately 1 hour, potentially delaying absorption of oral medications [2]. Patients with CKD frequently take medications with narrow therapeutic windows: tacrolimus, cyclosporine, metformin, or digoxin. A delay in peak concentration for these drugs may be clinically irrelevant for some and significant for others. Prescribers should review the full medication list before initiating bremelanotide in any patient with significant comorbidities.

Clinical Trial Safety Data: What RECONNECT Tells Us About Renal Events

The RECONNECT program was not designed to detect renal endpoints [5]. The trials excluded patients with clinically significant medical conditions, a category that would have captured most patients with eGFR <45. Renal function was not measured as a pre-specified secondary endpoint, and no systematic collection of urinary biomarkers was performed.

Adverse Event Profile From RECONNECT

Across both Phase 3 trials, the most common treatment-emergent adverse events were nausea (40.0% bremelanotide vs. 1.3% placebo), flushing (20.3% vs. 0%), and injection-site reactions (13.2% vs. 5.4%) [5]. The FDA label does not list any renal or urinary adverse event among those occurring in more than 2% of treated participants [2]. Two participants in the active-treatment arm had transient elevations in serum creatinine, reported as mild and resolving without intervention, though these were not adjudicated as drug-related adverse events in the published data [5].

The Limitation of Trial Exclusions

"The RECONNECT trials enrolled a relatively healthy premenopausal population," noted the original Obstet Gynecol publication's discussion section, directly acknowledging that results may not apply to women with significant comorbidities including renal impairment [5]. This is not a minor caveat. The average participant had a BMI of approximately 28 kg/m² and no significant cardiovascular or renal history, making extrapolation to a CKD population speculative.

Bremelanotide in Off-Label Male Use: Additional Renal Considerations

Bremelanotide is used off-label for erectile dysfunction in men, a population that substantially overlaps with CKD [9]. Men with CKD have a prevalence of erectile dysfunction exceeding 70% at eGFR stages 4 and 5 [9]. The blood pressure reduction associated with bremelanotide may be more consequential in men who are also receiving antihypertensives for CKD-related hypertension. No PDE5 inhibitor-style cardiovascular outcome data exist for bremelanotide, and combining it with nitrates is not studied.

Dosing Considerations in Men With CKD

Off-label male dosing typically mirrors the female label: 1.75 mg subcutaneously as needed [3]. Given the approximately 40% AUC increase predicted in severe impairment, some compounding pharmacies have explored 1.0 mg doses for men with eGFR <30. No published clinical data support this practice, and it falls entirely outside FDA labeling. Any prescriber choosing this path should document the rationale and obtain explicit informed consent about the absence of efficacy and safety data in this specific population.

Monitoring Recommendations for Patients With Renal Comorbidities

Patients with any degree of CKD who are prescribed bremelanotide should have structured monitoring in place before, during, and after treatment.

Baseline Assessment

Before the first dose, obtain a complete metabolic panel including serum creatinine, BUN, and a urine albumin-to-creatinine ratio (UACR). Calculate eGFR using the CKD-EPI 2021 equation, which the National Kidney Foundation endorses as the preferred estimation method [8]. Document blood pressure in both sitting and standing positions to screen for orthostatic hypotension.

On-Treatment Monitoring

Recheck serum creatinine and blood pressure after 4 to 6 weeks of use (assuming more than 4 doses in that window). A rise in creatinine exceeding 0.3 mg/dL above baseline or a new drop in eGFR exceeding 25% should prompt suspension of bremelanotide and nephrology consultation. These thresholds align with KDIGO acute kidney injury staging criteria [8].

Discontinuation Signals

Stop bremelanotide if the patient develops symptomatic hypotension, a new rise in UACR exceeding 30 mg/g above baseline, or any clinical sign of acute kidney injury. Persistent nausea, a common side effect, reduces oral hydration and can compound prerenal risk in susceptible patients.

What Melanocortin Research Means for Future Renal Therapeutics

The preclinical renal data on melanocortin agonism has generated genuine academic interest in this receptor class as a potential therapeutic target in nephrology, separate from HSDD [4]. Selective MC1R agonists are in early development for conditions including lupus nephritis and ischemia-reperfusion injury. Bremelanotide itself is not being studied for renal indications, but the mechanistic overlap is worth tracking.

Alpha-MSH Analogs in Nephrology Research

Synthetic alpha-MSH analogs, structurally similar to bremelanotide, have demonstrated dose-dependent reduction in cisplatin-induced nephrotoxicity in rodent models, reducing peak creatinine by 38% compared with vehicle controls in one published study [7]. The protective effect was abolished by selective MC1R antagonism, confirming receptor specificity. Whether a clinically achievable bremelanotide dose in humans produces sufficient MC1R occupancy in the kidney to replicate these findings is unknown.

The Gap Between Mechanism and Clinical Proof

Mechanistic plausibility is not clinical proof. The nephroprotective framing of bremelanotide that sometimes appears in telehealth marketing is not supported by prospective human data. Prescribers should not represent the drug to patients as kidney-protective, because doing so would overstate what the published literature demonstrates. The responsible position: the drug is not known to cause significant renal injury at the approved dose in patients with normal to mildly reduced kidney function, and preclinical data raise the possibility of renal benefit at pharmacologic MC1R occupancy, but clinical confirmation is absent.